Fenoterol
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy category |
|
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | ~6.5 hours[1][2][3][4] |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.205.960 |
| Chemical and physical data | |
| Formula | C17H21NO4 |
| Molar mass | 303.358 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Fenoterol is a β2-adrenergic receptor agonist and bronchodilator medication used in the treatment of asthma.
Fenoterol is produced and sold by Boehringer Ingelheim as Berotec N and in combination with ipratropium as Berodual N.
It was patented in 1962 and came into medical use in 1971,[5] but in the 1980s concerns emerged about its safety and its use being associated with an increased risk of death.
- ^ "Fenoterol Hydrobromide Drug Information, Professional". Drugs.com. 1996-01-01. Archived from the original on 2019-08-25. Retrieved 2018-06-11.
- ^ "Fenoterol - Drug Monograph". DrugInfoSys.com. 2016-10-27. Retrieved 2018-06-11.
- ^ "Berotec Inhalation Solution (Fenoterol HBr)". RxMed.com. Retrieved 2018-06-11.
- ^ Svedmyr N (1985-05-06). "Fenoterol: A Beta2-adrenergic Agonist for Use in Asthma; Pharmacology, Pharmacokinetics, Clinical Efficacy and Adverse Effects". Pharmacotherapy. 5 (3). Wiley: 109–126. doi:10.1002/j.1875-9114.1985.tb03409.x. ISSN 0277-0008. PMID 2991865. S2CID 189746.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 542. ISBN 9783527607495.